Corvus Pharmaceuticals

CRVS · NASDAQ

$10.23+$0.58 (+6.01%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $9.65

CRVS analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 9 analysts

Average $33.81 (+230.5% upside)

Low: $27.27
Now: $10.23
High: $44.10

Upgrades and downgrades

The latest rating actions, newest first

CRVS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Goldman Sachs	Apr 17, 2026	Initiates	Buy	$40.00	51%
Oppenheimer	Mar 13, 2026	Maintains	Outperform	$32.00 → $33.00	33%
Jefferies	Jan 22, 2026	Maintains	Buy	$13.00 → $42.00	46%
Oppenheimer	Jan 21, 2026	Maintains	Outperform	$15.00 → $32.00	33%
Barclays	Jan 21, 2026	Maintains	Overweight	$16.00 → $28.00	46%
HC Wainwright & Co.	Jan 20, 2026	Maintains	Buy	$11.00 → $27.00	42%

The case for and against

Updated Jul 7, 2026

Bull case

Corvus Pharmaceuticals is set to continue its strong performance, as it plans to initiate studies for its product candidates in various inflammatory and immune-mediated diseases, and it already has positive interim Phase 1b/2 AD results, positioning its lead candidate, soquelitinib as a leading oral treatment option. With a current price target of $27, and potential upside to its pipeline value of $3.1B, financial risks and potential milestones in 2026, Corvus is positioned for continued growth and success in the biopharmaceutical industry.

Bear case

Corvus Pharmaceuticals is facing strong headwinds as they continue to push their product candidate, soquelitinib, forward in a highly competitive market for treatments of immune-mediated diseases, inflammatory diseases, and cancers. While the recent financing efforts have provided some financial cushion, it will not be enough to offset the high costs associated with clinical trials and potential development setbacks. Additionally, the company's focus on only one primary business activity and one reportable segment leaves them vulnerable to any potential failures or setbacks with their lead candidate.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.